Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

12XE

Crystal structure of KRAS(Q61K) bound to GppNHp and ligand

This is a non-PDB format compatible entry.
Summary for 12XE
Entry DOI10.2210/pdb12xe/pdb
DescriptorIsoform 2B of GTPase KRas, (4P)-5-ethynyl-6-fluoro-4-(8-fluoro-2-{[(2R,4R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}-4-{(1R,5S)-8-[(1-methyl-1H-imidazol-4-yl)methyl]-3,8-diazabicyclo[3.2.1]octan-3-yl}pyrido[4,3-d]pyrimidin-7-yl)naphthalen-2-ol, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, ... (6 entities in total)
Functional Keywordskras, gtpase, gnp-bound, oncoprotein
Biological sourceHomo sapiens (human)
Total number of polymer chains1
Total formula weight20663.20
Authors
Wang, Y.-C.,Zhang, Z. (deposition date: 2026-04-21, release date: 2026-08-26)
Primary citationWang, Y.C.,Chen, S.C.,Cao, Y.,Wu, Y.,Shi, Z.,Wang, C.D.,Norinskiy, M.A.,Celik, H.,Zhang, Z.
Bronsted-basic small molecules activate GTP hydrolysis in KRAS-Q61 mutants.
Nat.Chem.Biol., 2026
Cited by
PubMed Abstract: The RAS family of oncogenes (KRAS, HRAS, NRAS) is among the most frequently mutated genes in human cancer. Therapeutic development has largely focused on inhibitors for KRAS codon 12 mutations, while mutant-selective inhibitors for Q61 variants remain elusive. A common mechanistic feature of G12 and Q61 mutants is the reduced efficiency of GTP hydrolysis, which enriches RAS in its active, signaling-competent state. Here we report small molecules that accelerate GTP hydrolysis in KRAS-Q61 mutants as an alternative therapeutic strategy. These compounds compensate for the loss of the catalytic residue Gln61 by introducing a general base into the active site, selectively enhancing hydrolysis of KRAS-Q61X (X = H, L, K, R) mutants by up to 20-fold. In mutant cancer cell lines, these compounds reduce GTP-bound RAS levels and suppress downstream signaling. This work establishes a mechanistic foundation for small-molecule 'GTPase activators' and offers a new paradigm for targeting RAS-driven cancers.
PubMed: 42587080
DOI: 10.1038/s41589-026-02291-1
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.01 Å)
Structure validation

259015

PDB entries from 2026-09-02

PDB statisticsPDBj update infoContact PDBjnumon